胃がんおよび食道がんの進行患者におけるBI 3706674の異なる投与量に対する忍容性を検証する研究

基本情報

NCT ID

NCT06056024

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

47

治験依頼者名

Boehringer Ingelheim

概要

This study is no longer open to new participants. It was a study in adults with advanced cancer in the stomach and oesophagus. This is a study for people for whom previous treatment was not successful or no treatment exists. In this study, BI 3706674 is given to humans for the first time. The purpose of this study is to find a suitable dose of BI 3706674 that people with advanced cancer can tolerate when taken alone. Another purpose is to check whether BI 3706674 can make tumours shrink. BI 3706674 blocks growth signals and may prevent the tumour from growing. Participants take BI 3706674 as a tablet when starting treatment. Different doses of BI 3706674 are tested during this study. If there is benefit for the participants and if they can tolerate it, the treatment is given up to the maximum duration of the study. During this time, participants visit the study site regularly. The total number of visits depends on how they respond to and tolerate the treatment. Doctors record any unwanted effects and regularly check the general health of the participants.

対象疾患

介入

依頼者（Sponsor）

実施施設 (2)